Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Activating FGFR2–RAS–BRAF Mutations in Ameloblastoma
Noah A. Brown, Delphine C.M. Rolland, Jonathan B. McHugh, et al.
Clinical Cancer Research (2014) Vol. 20, Iss. 21, pp. 5517-5526
Open Access | Times Cited: 247

Showing 1-25 of 247 citing articles:

Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Odontogenic and Maxillofacial Bone Tumors
John M. Wright, Marilena Vered
Head and Neck Pathology (2017) Vol. 11, Iss. 1, pp. 68-77
Open Access | Times Cited: 609
Ameloblastoma: current etiopathological concepts and management
OA Effiom, O M Ogundana, Abdulwarith Akinshipo, et al.
Oral Diseases (2017) Vol. 24, Iss. 3, pp. 307-316
Open Access | Times Cited: 261
Ameloblastoma: a clinical review and trends in management
Andrew C. McClary, Robert B. West, Ashley C. McClary, et al.
European Archives of Oto-Rhino-Laryngology (2015) Vol. 273, Iss. 7, pp. 1649-1661
Closed Access | Times Cited: 234
Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma
Liangqing Dong, Dayun Lu, Ran Chen, et al.
Cancer Cell (2021) Vol. 40, Iss. 1, pp. 70-87.e15
Closed Access | Times Cited: 227
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
Ian M. Silverman, Antoine Hollebecque, Luc Friboulet, et al.
Cancer Discovery (2020) Vol. 11, Iss. 2, pp. 326-339
Open Access | Times Cited: 208
Odontogenic Cysts and Neoplasms
Elizabeth Ann Bilodeau, Bobby Collins
Surgical pathology clinics (2016) Vol. 10, Iss. 1, pp. 177-222
Closed Access | Times Cited: 202
Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Nasal Cavity, Paranasal Sinuses and Skull Base
Lester D.�R. Thompson, Justin A. Bishop
Head and Neck Pathology (2022) Vol. 16, Iss. 1, pp. 1-18
Open Access | Times Cited: 70
BRAF V600E mutation-specific antibody: A review
Lauren L. Ritterhouse, Justine A. Barletta
Seminars in Diagnostic Pathology (2015) Vol. 32, Iss. 5, pp. 400-408
Closed Access | Times Cited: 149
Clinical and Radiographic Response With Combined BRAF-Targeted Therapy in Stage 4 Ameloblastoma
Frederic J. Kaye, Alison Marguerite Ivey, Walter E. Drane, et al.
JNCI Journal of the National Cancer Institute (2014) Vol. 107, Iss. 1, pp. dju378-dju378
Open Access | Times Cited: 129
Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours
Marina Gonçalves Diniz, Carolina Cavaliéri Gomes, Bruna Viana Antonini Guimarães, et al.
Tumor Biology (2015) Vol. 36, Iss. 7, pp. 5649-5653
Closed Access | Times Cited: 110
Ameloblastoma: A Review of Recent Molecular Pathogenetic Discoveries
Noah A. Brown, Bryan L. Betz
Biomarkers in Cancer (2015) Vol. 7s2, pp. BIC.S29329-BIC.S29329
Open Access | Times Cited: 106
Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
Senthil Damodaran, Fengmin Zhao, Dustin A. Deming, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 14, pp. 1552-1561
Open Access | Times Cited: 50
Adenoid Ameloblastoma Shares Clinical, Histologic, and Molecular Features With Dentinogenic Ghost Cell Tumor: The Histologic Spectrum of WNT Pathway–Altered Benign Odontogenic Tumors
Kyu‐Young Oh, Seong‐Doo Hong, Hye‐Jung Yoon
Modern Pathology (2023) Vol. 36, Iss. 3, pp. 100051-100051
Open Access | Times Cited: 23
METTL1 facilitates ameloblastoma invasive growth via MAPK signaling pathway
Yue Wang, Gan Xiong, Weixin Cai, et al.
Gene (2024) Vol. 905, pp. 148234-148234
Open Access | Times Cited: 8
Clinicopathological and Immunohistochemical Risk Predictors for Ameloblastoma Recurrence
Hévila de Figueiredo Pires, Glória Maria de França, Hannah Gil de Farias Morais, et al.
Head and Neck Pathology (2025) Vol. 19, Iss. 1
Closed Access | Times Cited: 1
BRAF inhibitor treatment of primary BRAF -mutant ameloblastoma with pathologic assessment of response
Serena Y. Tan, Jonathan R. Pollack, Michael J. Kaplan, et al.
Oral Surgery Oral Medicine Oral Pathology and Oral Radiology (2016) Vol. 122, Iss. 1, pp. e5-e7
Closed Access | Times Cited: 83
A Recurrent Mosaic Mutation in SMO , Encoding the Hedgehog Signal Transducer Smoothened, Is the Major Cause of Curry-Jones Syndrome
Stephen R.F. Twigg, Robert B. Hufnagel, Kerry A. Miller, et al.
The American Journal of Human Genetics (2016) Vol. 98, Iss. 6, pp. 1256-1265
Open Access | Times Cited: 82
The Mutational Profile of Unicystic Ameloblastoma
Kristiina Heikinheimo, J.-M. Huhtala, Alexandra Thiel, et al.
Journal of Dental Research (2018) Vol. 98, Iss. 1, pp. 54-60
Open Access | Times Cited: 79
BRAF‐V600E expression correlates with ameloblastoma aggressiveness
Eduardo Rodrigues Fregnani, Danyel Elias da Cruz Pérez, Oslei Paes de Almeida, et al.
Histopathology (2016) Vol. 70, Iss. 3, pp. 473-484
Closed Access | Times Cited: 77
The landscape of genetic alterations in ameloblastomas relates to clinical features
Sibel Elif Gültekin, Reem Aziz, Carina Heydt, et al.
Virchows Archiv (2018) Vol. 472, Iss. 5, pp. 807-814
Open Access | Times Cited: 70
BRAF p.V600E mutations are not unique to ameloblastoma and are shared by other odontogenic tumors with ameloblastic morphology
Philippe Brunner, Michel Bihl, Gernot Jundt, et al.
Oral Oncology (2015) Vol. 51, Iss. 10, pp. e77-e78
Closed Access | Times Cited: 69
Genetic basis of calcifying cystic odontogenic tumors
Akane Yukimori, Yu Oikawa, Keiichi Morita, et al.
PLoS ONE (2017) Vol. 12, Iss. 6, pp. e0180224-e0180224
Open Access | Times Cited: 69
Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation
Gustavo dos Santos Fernandes, Daniel M. Girardi, João Paulo Giacomini Bernardes, et al.
BMC Cancer (2018) Vol. 18, Iss. 1
Open Access | Times Cited: 69
Immunocytochemical markers of neuronal maturation in human diagnostic neuropathology
Harvey B. Sarnat
Cell and Tissue Research (2014) Vol. 359, Iss. 1, pp. 279-294
Closed Access | Times Cited: 68
Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma
Daniel L. Faden, Alain P. Algazi
JNCI Journal of the National Cancer Institute (2016) Vol. 109, Iss. 1
Open Access | Times Cited: 65
Page 1 - Next Page

Scroll to top